{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:17Z","timestamp":1740120077561,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12185-020-03038-x","type":"journal-article","created":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T11:02:47Z","timestamp":1606042967000},"page":"586-591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Monitoring of MYD88 L265P mutation by droplet digital polymerase chain reaction for prediction of early relapse in a patient with Bing\u2013Neel syndrome"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7605-7615","authenticated-orcid":false,"given":"Hisaharu","family":"Shikata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisafumi","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Matsukage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,22]]},"reference":[{"key":"3038_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/bjh.16167","volume":"187","author":"JJ Castillo","year":"2019","unstructured":"Castillo JJ, Treon SP. How we manage Bing\u2013Neel syndrome. Br J Haematol. 2019;187:277\u201385.","journal-title":"Br J Haematol"},{"key":"3038_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3324\/haematol.2016.147728","volume":"102","author":"MC Minnema","year":"2017","unstructured":"Minnema MC, Kimby E, D\u2019Sa S, Fornecker LM, Poulain S, Snijders TJ, et al. Guideline for the diagnosis, treatment and response criteria for Bing\u2013Neel syndrome. Haematologica. 2017;102:43\u201351.","journal-title":"Haematologica"},{"key":"3038_CR3","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1038\/bcj.2015.36","volume":"5","author":"T Nagao","year":"2015","unstructured":"Nagao T, Oshikawa G, Ishida S, Akiyama H, Umezawa Y, Nogami A, et al. A novel myd88 mutation, l265r pp, in waldenstr\u00f6m macroglobulinemia activates the nf-\u03bab pathway to upregulate bcl-xl expression and enhances cell survival. Blood Cancer J. 2015;5:e314.","journal-title":"Blood Cancer J"},{"key":"3038_CR4","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","volume":"123","author":"SE Herman","year":"2014","unstructured":"Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al. Ibrutinib inhibits bcr and nf-\u03bab signaling and reduces tumor proliferation in tissue-resident cells of patients with cll. Blood. 2014;123:3286\u201395.","journal-title":"Blood"},{"key":"3038_CR5","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","volume":"378","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Tedeschi A, Trotman J, Garc\u00eda-Sanz R, Macdonald D, Leblond V, et al. Phase 3 trial of ibrutinib plus rituximab in waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2018;378:2399\u2013410.","journal-title":"N Engl J Med"},{"key":"3038_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, et al. Ibrutinib for patients with rituximab-refractory waldenstr\u00f6m\u2019s macroglobulinaemia (innovate): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18:241\u201350.","journal-title":"Lancet Oncol"},{"key":"3038_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood-2018-10-879593","volume":"133","author":"JJ Castillo","year":"2019","unstructured":"Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, et al. Ibrutinib for the treatment of Bing\u2013Neel syndrome: a multicenter study. Blood. 2019;133:299\u2013305.","journal-title":"Blood"},{"key":"3038_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/bjh.14218","volume":"179","author":"C Mason","year":"2017","unstructured":"Mason C, Savona S, Rini JN, Castillo JJ, Xu L, Hunter ZR, et al. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of bing neel syndrome. Br J Haematol. 2017;179:339\u201341.","journal-title":"Br J Haematol"},{"key":"3038_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/cas.13450","volume":"109","author":"K Hattori","year":"2018","unstructured":"Hattori K, Sakata-Yanagimoto M, Suehara Y, Yokoyama Y, Kato T, Kurita N, et al. Clinical significance of disease-specific myd88 mutations in circulating DNA in primary central nervous system lymphoma. Cancer Sci. 2018;109:225\u201330.","journal-title":"Cancer Sci"},{"key":"3038_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3324\/haematol.2017.186528","volume":"103","author":"D Drandi","year":"2018","unstructured":"Drandi D, Genuardi E, Dogliotti I, Ferrante M, Jim\u00e9nez C, Guerrini F, et al. Highly sensitive myd88 (l265p) mutation detection by droplet digital polymerase chain reaction in waldenstr\u00f6m macroglobulinemia. Haematologica. 2018;103:1029\u201337.","journal-title":"Haematologica"},{"key":"3038_CR11","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","volume":"3","author":"P Kapoor","year":"2017","unstructured":"Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, et al. Diagnosis and management of waldenstr\u00f6m macroglobulinemia: mayo stratification of macroglobulinemia and risk-adapted therapy (msmart) guidelines 2016. JAMA Oncol. 2017;3:1257\u201365.","journal-title":"JAMA Oncol"},{"key":"3038_CR12","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/bjh.13078","volume":"167","author":"S Poulain","year":"2014","unstructured":"Poulain S, Boyle EM, Roumier C, Demarquette H, Wemeau M, Geffroy S, et al. Myd88 l265p mutation contributes to the diagnosis of bing neel syndrome. Br J Haematol. 2014;167:506\u201313.","journal-title":"Br J Haematol"},{"key":"3038_CR13","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.clml.2015.11.004","volume":"16","author":"AM Frustaci","year":"2016","unstructured":"Frustaci AM, Rusconi C, Picardi P, Veronese S, Montillo M, Cairoli R, et al. Bing neel syndrome in a previously untreated patient with waldenstr\u00f6m\u2019s macroglobulinemia: contribution of myd88 l265p mutation on cerebrospinal fluid. Clin Lymphoma Myeloma Leuk. 2016;16:e7-9.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3038_CR14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.241208","author":"S Bobillo","year":"2020","unstructured":"Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2020. https:\/\/doi.org\/10.3324\/haematol.2019.241208 ([published online ahead of print February 20, 2020]).","journal-title":"Haematologica"},{"key":"3038_CR15","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1080\/10428194.2017.1369074","volume":"59","author":"LS Hiemcke-Jiwa","year":"2018","unstructured":"Hiemcke-Jiwa LS, Leguit RJ, Radersma-van Loon JH, Westerweel PE, Rood JJM, Doorduijn JK, et al. Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement. Leuk Lymphoma. 2018;59:1256\u20139.","journal-title":"Leuk Lymphoma"},{"key":"3038_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/ajh.25023","volume":"93","author":"JN Gustine","year":"2018","unstructured":"Gustine JN, Meid K, Dubeau T, Severns P, Hunter ZR, Guang Y, et al. Ibrutinib discontinuation in waldenstr\u00f6m macroglobulinemia: etiologies, outcomes, and igm rebound. Am J Hematol. 2018;93:511\u20137.","journal-title":"Am J Hematol"},{"key":"3038_CR17","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","volume":"36","author":"SP Treon","year":"2018","unstructured":"Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, et al. Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2018;36:2755\u201361.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03038-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-020-03038-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03038-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T18:27:07Z","timestamp":1616437627000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-020-03038-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,22]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["3038"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-03038-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2020,11,22]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Off-label use of ibrutinib for this patient with BNS was approved by the Institutional Review Board of Uwajima City Hospital (IRB number: 1911-262). Written informed consent was also obtained from the patient for off-label use.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}